Perioperative Management of Catecholamine-Secreting Glomus Jugulare Tumors

Abstract

To treat patients with a catecholamine-secreting glomus jugulare tumor, perioperative management is important. Perioperative catecholamine hypersecretion causes severe problems in the treatment of a catecholamine-secreting glomus tumor. Therefore, a precise therapeutic strategy and perioperative management are required through collaboration of the endocrinology, anesthesiology, and endocrine surgery departments . We describe our perioperative management for catecholamine-secreting glomus jugulare tumor. The patient was a 31-year-old woman with a 50-mm glomus jugulare tumor and a significantly elevated plasma noradrenaline level of 21,165 pg/ml. Before the surgery, oral α − blocker administration was initiated for ∼ 3 months, and her body weight increased from 52 kg at the time of examination to 54.2 kg. Coil embolization of the tumor vessel was performed 1 week before surgery, and the intense tumor stain was reduced by 90%. The patient underwent almost total removal of the tumor via mastoidectomy with high cervical exposure via the transsigmoid approach. Postoperatively, plasma noradrenaline decreased markedly. Preoperative pharmacologic stabilization and peri- and postoperative anesthetic management are essential for the treatment of a catecholamine-secreting glomus jugulare tumor.

Keywords

glomus jugular tumor - pheochromocytoma - catecholamine - surgical strategy - skull base surgery

• References

• 1 Guild SR. A hitherto unrecognized structure, the glomus jugularis in man. Anat Rec 1941; 79 (Suppl. 02) 28
• 2 Rosenwasser H. Carotid body tumor of the middle ear and mastoid. Arch Otolaryngol 1945; 41: 64-67
• 3 Winship T, Klopp CT, Jenkins WH. Glomus-jugularis tumors. Cancer 1948; 1 (3) 441-448
• 4 Al-Mefty O, Teixeira A. Complex tumors of the glomus jugulare: criteria, treatment, and outcome. J Neurosurg 2002; 97 (6) 1356-1366
• 5 Kuhweide R, Lanser MJ, Fisch U. Catecholamine-secreting paragangliomas at the skull base. Skull Base Surg 1996; 6 (1) 35-45
• 6 Motegi H, Terasaka S, Yamaguchi S, Kobayashi H, Asaoka K, Iwasaki Y. A case of catecholamine-secreting glomus jugulare tumor: treatment strategy and perioperative management. [in Japanese]. No Shinkei Geka 2008; 36 (11) 1029-1034
• 7 Schwaber MK, Glasscock ME, Nissen AJ, Jackson CG, Smith PG. Diagnosis and management of catecholamine secreting glomus tumors. Laryngoscope 1984; 94 (8) 1008-1015
• 8 Jackson CG. Neurotologic skull base surgery for glomus tumors. Diagnosis for treatment planning and treatment options. Laryngoscope 1993; 103 (11 Pt 2) (Suppl. 60) 17-22
• 9 Nelson MD, Kendall BE. Intracranial catecholamine secreting paragangliomas. Neuroradiology 1987; 29 (3) 277-282
• 10 Matishak MZ, Symon L, Cheeseman A, Pamphlett R. Catecholamine-secreting paragangliomas of the base of the skull. Report of two cases. J Neurosurg 1987; 66 (4) 604-608
• 11 Jensen NF. Glomus tumors of the head and neck: anesthetic considerations. Anesth Analg 1994; 78 (1) 112-119
• 12 Prys-Roberts C. Phaeochromocytoma—recent progress in its management. Br J Anaesth 2000; 85 (1) 44-57
• 13 Colen TY, Mihm FG, Mason TP, Roberson JB. Catecholamine-secreting paragangliomas: recent progress in diagnosis and perioperative management. Skull Base 2009; 19 (6) 377-385
• 14 Goutcher CM, Cossar DF, Ratnasabapathy U, Burke AM. Magnesium in the management of catecholamine-secreting glomus tumours with intracranial extension. Can J Anaesth 2006; 53 (3) 316-321
• 15 Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth 1999; 83 (2) 302-320
• 16 Süzer T, Coskun E, Islekel H, Tahta K. Neuroprotective effect of magnesium on lipid peroxidation and axonal function after experimental spinal cord injury. Spinal Cord 1999; 37 (7) 480-484